CH3 BioSystems LLC is a biotechnology company organized around intellectual property created through research in chemical biology and epigenetics. The products derived from this research enable our end users, Biologists, Chemists and Clinicians, to create new diagnostics and potential therapeutic treatments for human and animal diseases. We manufacturer molecular tools for faster, more efficient and safer methods to facilitate research discoveries. Our patented CH3 antibody and other IP protected products provide scientists with a novel molecular toolkit to study protein methylation status in diseases like cancer, HIV and neurodevelopmental, autoimmune or cardiovascular disordered. Our vision is to promote the growth of the field of protein methylation biology and to provide cutting edge clinically relevant pharmaceutical products of the 21st century.